131.40 USD
↗ 1.57 (1.21%)AT CLOSE (11:59 AM EDT)
Gilead Sciences Inc
GILDNASDAQ • USD
131.06
↘ 0.34 (0.26%)
POST MARKET (AS OF 06:55 PM EDT)
Post Market
AS OF 06:55 PM EDT
131.06
↘ 0.34 (0.26%)
Market: OPEN
Gilead Sciences Inc (GILD) trades at $131.06 per share. The stock presents a bullish profile across the board: both technical indicators and our fundamental models signal a "Strong Buy" and "Strong Buy" respectively. Notable factors include a robust Altman Z-Score, a strong Piotroski F-Score of 7/9, exceptional Return on Equity (39.2%) and a bullish Golden Cross on the moving averages. Valuation metrics place GILD at a fair price relative to peers.
Technical & fundamental data as of Jul 13, 2026.
Open?$129.66
High?$131.67
Low?$127.94
Prev. Close?$129.83
Volume?5.1M
Avg. Volume?9.1M
VWAP?$130.57
Rel. Volume?0.56x
Bid / Ask
Bid?$122.50 × 100
Ask?$137.59 × 100
Spread?$15.09
Midpoint?$130.05
Valuation & Ratios
Market Cap?161.2B
Shares Out?1.2B
Float?926.2M
Float %?74.6%
P/E Ratio?17.49
P/B Ratio?6.85
EPS?$7.42
Dividend?2.50%
Ex-Dividend?N/A
News
Profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Themes
Employees
17.0K
Market Cap
161.2B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1992-01-22
Address
333 LAKESIDE DR
FOSTER CITY, CA 94404
Phone: (650) 574-3000
FOSTER CITY, CA 94404
Phone: (650) 574-3000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookStrong Buy
Strong SellNeutralStrong Buy
F-Score?88
Z-Score?97
Momentum?83
Short Sent.?79
Piotroski F-Score?7/9Strong
Altman Z-Score?4.63Safe
Confidence?82%High
Short InterestLow
Short % of Float?2.75%Low
Short Interest?25.5M
Days to Cover?2.7
Free Float926.2M
Avg Daily Volume9.6M
Settlement Date2026-06-30
Financial Health
Current Ratio?1.97Adequate
Quick Ratio?1.77Adequate
Cash Ratio?0.80Adequate
Debt/Equity?0.94Moderate
ValuationFAIRLY VALUEDvs 9 peers + S&P 500
Score78/100
P/E?17.5CHEAP▾
Peers88
S&P73
P/B?6.85FAIR▾
Peers22
S&P27
P/S?5.42FAIR▾
Peers60
S&P26
P/FCF?15.8CHEAP▾
Peers88
S&P71
EV/EBITDA?12.1FAIR▾
Peers88
S&P68
EV/Sales?5.91FAIR▾
Peers70
S&P29
Returns & Efficiency
ROE?39.2%STRONG▾
Peers86
S&P87
ROA?16.4%STRONG▾
Peers88
S&P90
Cash Flow & Enterprise
FCF?$10.2B
Enterprise Value?$175.7B
Fundamentals ratios updated end of day